See today's BioWorld Asia
To read the full story, subscribe or sign in.

Arctic Vision closes $32M series A to move lead product to clinic

July 21, 2020
By Bryan Wong
HONG KONG – Chinese eye disease specialist Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $32 million in a series A financing round to advance its lead program, ARVN-001 (triamcinolone acetonide suprachoroidal injectable suspension).
BioWorld Asia Financings Ocular Series A China